LB
Almirall, S.A.
LBTSF · OTC
$15.35 -0.78% (-$0.12)
Market Cap 2.84B €
P/E Ratio 67.48x
Div. Yield 1.09%
ROE 2.84%
Bulios Fair Price
$8.63
43.8% downside
Current Price
$15.35
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LBTSF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
34 /100
Fair P/FCF 94.72x
P/E 67.48x
P/B 1.92x
Growth
11 /100
Declining FCF growth 35.07%
EPS growth 65.15%
Book val. growth 0.99%
Profitability
42 /100
Moderate Op. margin 7.01%
Gross margin 76.87%
FCF margin 2.77%
Quality
15 /100
Poor ROA 1.78%
ROIC 2.46%
Asset turnover 0.46x
Debt
87 /100
Low Int. coverage 2.74x
Debt/Equity 0.23x
Net debt/EBITDA -0.18x
Stability
3 /100
Unstable EPS volatility 134.68%
Beta 0.18x
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LBTSF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Carlos Gallardo Piqué
Employees
2,026
Headquarters
Barcelona
Upcoming events
09 NOV
Earnings
Upcoming earnings report